Semaglutide is a medication available as an injection or tablets, used to treat type 2 diabetes and obesity. Semaglutide helps type-2 diabetics control blood sugar levels by enhancing the release of insulin, thereby lowering blood glucose levels.
This process also slows digestion and reduces appetite therefore making Semaglutide an effective weight-loss treatment.
In the U.K the most widely available brands of Semaglutide are Wegovy, Ozempic and Rybelsus.
WeGovy is licensed for weight loss, whilst Ozempic and Rybelsus are primarily used to treat type-2 diabetes.
However on occasion doctors may prescribe Ozempic ‘off-label’ for weight-loss or Rybelsus as an oral Semaglutide weight loss product.
Brand | Licensed to Treat | Formulation |
Ozempic | Type 2 Diabetes | Injection |
Rybelsus | Type 2 Diabetes | Tablet |
WeGovy | Weight loss | Injection |
Weight loss injection Semaglutide is considered one of the most effective weight loss treatments available.
A 2021 phase 3 clinical trial found a dosage of 2.4mg weekly Semaglutide injection produced a mean weight loss of 14.9%. Far greater than the 2.4% weight loss seen with the placebo.
[1] Chronic Weight Results | Wegovy® (semaglutide) injection 2.4 mg (novomedlink.com)
Common of very common side effects include:
Appetite decreased; burping; cholelithiasis (gallstones); constipation; diarrhea; fatigue; gastrointestinal discomfort; gastrointestinal disorders; hypoglycaemia (in combination with other antidiabetic drugs, in patients with type 2 diabetes); nausea; vomiting; weight decrease (in type 2 diabetes patients.)
Uncommon:
Pancreatitis acute; tastes altered
Semaglutide for Weight Loss is recommended for patients with a BMI of 30kg/m2 (or 27kg/m2 where there is at least one weight-related co-morbidity.) You can calculate your BMI using the calculator on the NHS website.
Those with a BMI of 30kg/m2 BMI or greater would be consider clinically obese and likely to be considered with Semaglutide weight loss UK treatment.
Semaglutide is a prescription-only medications. Ultimately prescribing decisions are made by doctors on a case-by-case basis. However there are specific groups where Semaglutide for weight management is not recommend. These include (but are not limited to):
An alternative weight management medication is Orlistat (Xenical.) Studies on Orlistat do show clinically significant weight loss results. However Semaglutide is shown to be more effective than Orlistat (Xenical)
Mounjaro (Tirzepatide) is another popular weight loss treatment. Mounjaro activates two hormones that help control appetite and blood sugar. WeGovy works similarly but only targets one of those hormones, making Mounjaro potentially more effective.
Semaglutide for Weight Loss is recommended for patients with a BMI of 30kg/m2 (or 27kg/m2 where there is at least one weight-related co-morbidity.)
Those with a BMI of 30kg/m2 BMI or greater would be consider clinically obese and likely to be considered with Semaglutide weight loss UK treatment.
Clinical studies shows a reduction of 4% in body weight after 3 months and 9% after 6 months amongst those taking subcutaneous Semaglutide injections for weight loss.
Whilst weight loss varies person to person, patients can expect to start ‘seeing’ noticeable reductions in key measurements such as BMI and weight after 3-6 months
In the UK Semaglutide is a prescription-only medication. You can buy Semaglutide for weight loss at Meds for Less after completing a short text based consultation with a doctor.
Semaglutide is a prescription only medications, so dosing is at the prescribing doctors discretion however, a typical WeGovy treatment plan may look something like:
Fast, Discreet, and Convenient
We're here to support :)
We are available Monday through Friday from 9am to 4pm. Do not use this service if you need urgent assistance. You should call 111 or 999 in an emergency. See our help section for more information.
Payment Options